Table of Content

1 Middle East Precision Medicine Market
1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.1.2 Key Questions Answered in the Report
1.2 Research Methodology
1.2.1 Primary Data Sources
1.2.2 Secondary Data Sources
1.3 Market Estimation Model

2 Market Overview
2.1 Market Definition
2.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric Medicine
2.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
2.4 Precision Medicine: Enabling Technologies and Applications
2.4.1 Innovators
2.4.1.1 3D DNA Printing
2.4.1.1.1 Introduction
2.4.1.1.2 Role of 3D DNA Printing
2.4.1.2 RNA-Seq
2.4.1.2.1 Introduction
2.4.1.2.2 Role of RNA-Seq in Precision Medicine
2.4.1.2.3 Key Players
2.4.1.3 4D Molecular Imaging
2.4.1.3.1 Introduction
2.4.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
2.4.1.3.3 Key Players
2.4.2 Early Adopters
2.4.2.1 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
2.4.2.1.1 Introduction
2.4.2.1.2 Role of CRISPR in Precision Medicine
2.4.2.1.3 Key Players
2.4.2.2 Blockchain
2.4.2.2.1 Introduction
2.4.2.2.2 Role of Blockchain in Precision Medicine
2.4.2.2.3 Key Players
2.4.2.3 Imaging Informatics
2.4.2.3.1 Introduction
2.4.2.3.2 Role of Imaging Informatics in Precision Medicine
2.4.2.3.3 Key Players
2.4.3 Early Majority
2.4.3.1 Artificial Intelligence (AI)
2.4.3.1.1 Introduction
2.4.3.1.2 Role of Artificial Intelligence in Precision Medicine
2.4.3.1.3 Key Players
2.4.3.2 Circulating Free DNA (cfDNA)
2.4.3.2.1 Introduction
2.4.3.2.2 Role of cfDNA in Precision Medicine
2.4.3.2.3 Key Players
2.4.3.3 Big Data
2.4.3.3.1 Introduction
2.4.3.3.2 Role of Big Data in Precision Medicine
2.4.3.3.3 Key Players
2.4.3.4 Next-Generation Sequencing (NGS)
2.4.3.4.1 Introduction
2.4.3.4.2 Role of NGS in Precision Medicine
2.4.3.4.3 Key Players
2.4.3.5 Health Informatics
2.4.3.5.1 Introduction
2.4.3.5.2 Role of Health Informatics in Precision Medicine
2.4.3.5.3 Key players
2.4.3.6 Bioinformatics
2.4.3.6.1 Introduction
2.4.3.6.2 Role of Bioinformatics in Precision Medicine
2.4.3.6.3 Key Players
2.4.4 Late Majority
2.4.4.1 Polymerase Chain Reactions (PCR)
2.4.4.1.1 Introduction
2.4.4.1.2 Role of PCR in Precision Medicine
2.4.4.1.3 Key players
2.4.4.2 Microarray
2.4.4.2.1 Role of Microarray in Precision Medicine
2.4.4.2.2 Key Players
2.5 COVID-19 Impact on the Middle East Precision Medicine Market

3 Industry Insights
3.1 Patent Analysis
3.2 Legal Requirements and Regulations

4 Competitive Landscape
4.1 Synergistic Activities
4.2 Product Launches, Enhancements, and Upgradation
4.3 Mergers and Acquisitions
4.4 Business Expansion

5 Market Dynamics
5.1 Market Drivers
5.1.1 Advancement of Sequencing Technologies
5.1.2 Rising Prevalence of Chronic Diseases
5.1.3 Shifting the Significance in Medicine from Reaction to Prevention
5.1.4 Reducing Adverse Drug Reactions through Pharmacogenomics Test
5.1.5 Potential to Reduce the Overall Healthcare Cost Across the Globe
5.2 Market Restraints
5.2.1 Unified Framework for Data Integration
5.2.2 Limited Knowledge about Molecular Mechanism/Interaction
5.2.3 Lack of Robust Reimbursement Landscape
5.3 Market Opportunities
5.3.1 Targeted Gene Therapy
5.3.2 Expansion into Emerging Markets
5.3.3 Collaborations and Partnerships across Value Chain to Accelerate Market Entry

6 Middle East Precision Medicine Market, by Ecosystem, $Million, 2021 - 2032
6.1 Overview
6.2 Applied Sciences
6.3 Precision Therapeutics
6.4 Digital Health and Information Technology
6.5 Precision Diagnostics

7 Middle East Precision Medicine Market, by Application, $Million, 2021 - 2032
7.1 Overview
7.2 Oncology
7.3 Infectious Diseases
7.4 Neurology
7.5 Endocrinology
7.6 Cardiology
7.7 Gastroenterology
7.8 Other Applications

8 Middle East Precision Medicine Market, by End-User, $Million, 2021 - 2032
8.1 Overview
8.2 Biopharmaceutical Companies
8.3 Diagnostic Companies
8.4 Other End Users

9 Middle East Precision Medicine Market, by Country, $Million, 2021-2032
9.1 Overview
9.1.1 K.S.A.
9.1.2 Israel
9.1.3 U.A.E.
9.1.4 Egypt
9.1.5 Iran
9.1.6 Qatar
9.1.7 Other Countries

10 Market - Competitive Benchmarking & Company Profiles
10.1 Overview
10.2 Abbott.
10.2.1 Company Overview
10.2.2 Role of Abbott. in the Middle East Precision Medicine Market
10.2.3 Key Competitors of the Company
10.2.4 Key Customers of the Company
10.2.5 Financials
10.2.6 Key Insights about the Financial Health of the Company
10.2.7 SWOT Analysis
10.3 Bio-Rad Laboratories, Inc.
10.3.1 Company Overview
10.3.2 Role of Bio-Rad Laboratories, Inc. in the Middle East Precision Medicine Market
10.3.3 Key Competitors of the Company
10.3.4 Key Customers of the Company
10.3.5 Business Strategies
10.3.6 Financials
10.3.7 Key Insights about the Financial Health of the Company
10.3.8 SWOT Analysis
10.4 ASURAGEN, INC.
10.4.1 Company Overview
10.4.2 Role of ASURAGEN, INC. in the Middle East Precision Medicine Market
10.4.3 Key Competitors of the Company
10.4.4 Key Customers of the Company
10.4.5 SWOT Analysis
10.5 bioM?rieux SA
10.5.1 Company Overview
10.5.2 Role of bioM?rieux SA in the Middle East Precision Medicine Market
10.5.3 Key Competitors of the Company
10.5.4 Key Customers of the Company
10.5.5 Financials
10.5.6 Key Insights about the Financial Health of the Company
10.5.7 SWOT Analysis
10.6 Diginova Health Solutions Ltd.
10.6.1 Company Overview
10.6.2 Role of Diginova Health Solutions Ltd. in the Middle East Precision Medicine Market
10.6.3 Key Competitors of the Company
10.6.4 Key Customers of the Company
10.6.5 Corporate Strategies
10.6.5.1 Product Launches and Upgradation
10.6.6 SWOT Analysis
10.7 F. Hoffmann-La Roche Ltd
10.7.1 Company Overview
10.7.2 Role of F. Hoffmann-La Roche Ltd in the Middle East Precision Medicine Market
10.7.3 Key Competitors of the Company
10.7.4 Key Customers of the Company
10.7.5 Business Strategies
10.7.6 Corporate Strategies
10.7.7 Key Insights about the Financial Health of the Company
10.7.8 SWOT Analysis
10.8 GlaxoSmithKline plc.
10.8.1 Company Overview
10.8.2 Role of GlaxoSmithKline plc. in the Middle East Precision Medicine Market
10.8.3 Key Competitors of the Company
10.8.4 Key Customers of the Company
10.8.5 Financials
10.8.6 Key Insights about the Financial Health of the Company
10.8.7 SWOT Analysis
10.9 Illumina, Inc.
10.9.1 Company Overview
10.9.2 Role of Illumina, Inc. in the Middle East Precision Medicine Market
10.9.3 Key Competitors of the Company
10.9.4 Key Customers of the Company
10.9.5 Financials
10.9.6 Key Insights about the Financial Health of the Company
10.9.7 SWOT Analysis
10.1 Intomics
10.10.1 Company Overview
10.10.2 Role Intomics in the Middle East Precision Medicine Market
10.10.3 Key Competitors of the Company
10.10.4 Key Customers of the Company
10.10.5 SWOT Analysis
10.11 Merck KGaA
10.11.1 Company Overview
10.11.2 Role of Merck KGaA in the Middle East Precision Medicine Market
10.11.3 Key Competitors of the Company
10.11.4 Key Customers of the Company
10.11.5 Financials
10.11.6 Key Insights about the Financial Health of the Company
10.11.7 SWOT Analysis
10.12 Novartis AG
10.12.1 Company Overview
10.12.2 Role of Novartis AG in the Middle East Precision Medicine Market
10.12.3 Key Competitors of the Company
10.12.4 Key Customers of the Company
10.12.5 Financials
10.12.6 Key Insights about the Financial Health of the Company
10.12.7 SWOT Analysis
10.13 Thermo Fisher Scientific Inc.
10.13.1 Company Overview
10.13.2 Role of Thermo Fisher Scientific Inc. in the Middle East Precision Medicine Market
10.13.3 Key Competitors of the Company
10.13.4 Key Customers of the Company
10.13.5 Financials
10.13.6 Key Insights about the Financial Health of the Company
10.13.7 SWOT Analysis
List of Figures
Figure 1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing, 2009-2025
Figure 2: Middle East Precision Medicine Market Segmentation
Figure 3: Primary Research Methodology
Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
Figure 5: COVID-19 Impact on the Middle East Precision Medicine Market
Figure 6: Patent Analysis
Figure 7: Role of FDA in Advancing Precision Medicine
Figure 8: Synergistic Activities Share (by Company), January 2012-July 2020
Figure 9: Product Launches, Enhancements, and Upgradation Share (by Company), January 2012-July 2020
Figure 10: Mergers and Acquisitions Share (by Company), January 2012-July 2020
Figure 11: Business Expansion Share (by Company), January 2012-July 2020
Figure 12: Precision Medicine Ecosystem
Figure 13: Middle East Precision Medicine Market (Applied Sciences)
Figure 14: Middle East Precision Medicine Market (Applied Sciences), $Million, 2021-2032
Figure 15: Middle East Precision Medicine Market (by Applied Sciences), $Million, 2021-2032
Figure 16: Middle East Precision Medicine Market (Precision Therapeutics), $Million, 2021-2032
Figure 17: Middle East Precision Medicine Market (by Precision Therapeutics), $Million, 2021 and 2032
Figure 18: Middle East Precision Medicine Market (Digital Health and Information Technology), $Million, 2021-2032
Figure 19: Middle East Precision Medicine Market (by Digital Health and Information Technology), $Million, 2021 and 2032
Figure 20: Middle East Precision Medicine Market (Precision Diagnostics)
Figure 21: Middle East Precision Medicine Market (Precision Diagnostics), $Million, 2021-2032
Figure 22: Middle East Precision Medicine Diagnostics Market (by Precision Diagnostics), $Million, 2021-2032
Figure 23: Middle East Precision Medicine Market (by Application)
Figure 24: Middle East Precision Medicine Market (by Application), $Million, 2021 and 2032
Figure 25: Types of Cancer
Figure 26: Middle East Precision Medicine Market (Oncology), $Million, 2021-2032
Figure 27: Middle East Precision Medicine Market (Infectious Diseases), $Million, 2021-2032
Figure 28: Clinical Trials Number in the Middle East, 2010 and 2020
Figure 29: Middle East Precision Medicine Market (Neurology), $Million, 2021-2032
Figure 30: Middle East Precision Medicine Market (Endocrinology), $Million, 2021-2032
Figure 31: Middle East Precision Medicine Market (Cardiology), $Million, 2021-2032
Figure 32: Middle East Precision Medicine Market (Gastroenterology), $Million, 2021-2032
Figure 33: Middle East Precision Medicine Market (Other Applications), $Million, 2021-2032
Figure 34: Middle East Precision Medicine Market (by End User)
Figure 35: Middle East Precision Medicine Market (by End User), $Million, 2021 and 2032
Figure 36: Middle East Precision Medicine Market, (Biopharmaceutical Companies), $Million, 2021-2032
Figure 37: Middle East Precision Medicine Market (Diagnostic Companies), $Million, 2021-2032
Figure 38: Middle East Precision Medicine Market (Other End Users), $Million, 2021-2032
Figure 39: Middle East Precision Medicine Market (by Country), $Million, 2021-2032
Figure 40: Middle East Precision Medicine Market (by Country), $Million, 2021 and 2032
Figure 41: Middle East Precision Medicine Market (K.S.A.), $Million, 2021-2032
Figure 42: Middle East Precision Medicine Market (Israel), $Million, 2021-2032
Figure 43: Middle East Precision Medicine Market (U.A.E.), $Million, 2021-2032
Figure 44: Middle East Precision Medicine Market (Egypt), $Million, 2021-2032
Figure 45: Middle East Precision Medicine Market (Iran), $Million, 2021-2032
Figure 46: Middle East Precision Medicine Market (Qatar), $Million, 2021-2032
Figure 47: Middle East Precision Medicine Market (Other Countries), $Million, 2021-2032
Figure 48: Total Number of Companies Profiled
Figure 49: Abbott.: Overall Product Portfolio
Figure 50: Abbott.: Overall Financials, $Million, 2019-2021
Figure 51: Abbott.: Revenue (by Segment), $Million, 2019-2021
Figure 52: Abbott.: Revenue (by Region), $Million, 2019-2021
Figure 53: Abbott.: R&D Expenditure, $Million, 2019-2021
Figure 54: Abbott.: SWOT Analysis
Figure 55: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 56: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 57: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 58: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 59: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 60: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 61: ASURAGEN, INC.: Overall Product Portfolio
Figure 62: ASURAGEN, INC.: SWOT Analysis
Figure 63: bioM?rieux SA: Product Portfolio
Figure 64: bioM?rieux SA: Overall Financials, $Million, 2019-2021
Figure 65: bioM?rieux SA: Revenue (by Segment), $Million, 2019-2021
Figure 66: bioM?rieux SA: Revenue (by Region), $Million, 2019-2021
Figure 67: bioM?rieux SA: R&D Expenditure, $Million, 2019-2021
Figure 68: bioM?rieux SA: SWOT Analysis
Figure 69: Diginova Health Solutions Ltd.: Product Portfolio
Figure 70: Diginova Health Solutions Ltd.: SWOT Analysis
Figure 71: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 72: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 73: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
Figure 74: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
Figure 75: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 76: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 77: GlaxoSmithKline plc.: Overall Product Portfolio
Figure 78: GlaxoSmithKline plc.: Overall Financials, $Million, 2019-2021
Figure 79: GlaxoSmithKline plc.: Revenue (by Segment), $Million, 2019-2021
Figure 80: GlaxoSmithKline plc.: Revenue (by Region), $Million, 2019-2021
Figure 81: GlaxoSmithKline plc.: R&D Expenditure, $Million, 2019-2021
Figure 82: GlaxoSmithKline plc.: SWOT Analysis
Figure 83: Illumina, Inc.: Product Portfolio
Figure 84: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 85: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 86: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 87: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 88: Illumina, Inc.: SWOT Analysis
Figure 89: Intomics: SWOT Analysis
Figure 90: Merck KGaA: Product Portfolio
Figure 91: Merck KGaA: Overall Financials, $Million, 2019-2021
Figure 92: Merck KGaA: Revenue (by Segment), $Million, 2019-2021
Figure 93: Merck KGaA: Revenue (by Region), $Million, 2019-2021
Figure 94: Merck KGaA: R&D Expenditure, $Million, 2019-2021
Figure 95: Merck KGaA: SWOT Analysis
Figure 96: Novartis AG: Overall Product Portfolio
Figure 97: Novartis AG: Overall Financials, $Million, 2019-2021
Figure 98: Novartis AG: Revenue (by Segment), $Million, 2019-2021
Figure 99: Novartis AG: Revenue (by Region), $Million, 2019-2021
Figure 100: Novartis AG: R&D Expenditure, $Million, 2019-2021
Figure 101: Novartis AG: SWOT Analysis
Figure 102: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 103: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 104: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 105: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 106: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 107: Thermo Fisher Scientific Inc.: SWOT Analysis
List of Tables
Table 1: Estimated Number of Cancer Incident Cases, 2018 and 2040